Group 1 - The company held its 17th meeting of the 10th Board of Directors on October 13, 2025, with all 9 directors present, including 3 independent directors [2][4] - The meeting approved the proposal to cancel the Supervisory Board, change the registered capital, and amend the Articles of Association, which will be submitted to the first extraordinary general meeting of shareholders in 2025 for special resolution [3][58] - The registered capital will increase from 514,317,177 yuan to 514,348,244 yuan due to the conversion of convertible bonds during the conversion period [58] Group 2 - The company plans to revise several management systems in accordance with the latest legal requirements, with some revisions requiring approval from the shareholders' meeting [5][38] - The company approved the renewal of the accounting firm Rongcheng Certified Public Accountants for the 2025 audit, pending authorization from the shareholders' meeting [39][52] - The first extraordinary general meeting of shareholders in 2025 is scheduled for October 29, 2025 [43]
上海科华生物工程股份有限公司 第十届董事会第十七次会议决议公告